Search results
Showing 7621 to 7635 of 8211 results
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.
More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Check our list of appointed suppliers to find out which knowledge resources and services they can offer.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Our system implementation team works with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area, ensuring regular interaction with our stakeholders.
Details and meeting dates of the antimicrobials evaluation panel
Tell us what matters to you, your organisation or your community.
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.